208 related articles for article (PubMed ID: 23762458)
1. Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice.
Wozniak DF; Diggs-Andrews KA; Conyers S; Yuede CM; Dearborn JT; Brown JA; Tokuda K; Izumi Y; Zorumski CF; Gutmann DH
PLoS One; 2013; 8(6):e66024. PubMed ID: 23762458
[TBL] [Abstract][Full Text] [Related]
2. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.
Brown JA; Emnett RJ; White CR; Yuede CM; Conyers SB; O'Malley KL; Wozniak DF; Gutmann DH
Hum Mol Genet; 2010 Nov; 19(22):4515-28. PubMed ID: 20826448
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of pharmacological inhibition of anaplastic lymphoma kinase in neurofibromatosis 1 mutant mice.
Krenik D; Weiss JB; Raber J
Behav Brain Res; 2022 Apr; 423():113767. PubMed ID: 35077772
[TBL] [Abstract][Full Text] [Related]
4. Role of the parental NF1 carrier in effects of pharmacological inhibition of anaplastic lymphoma kinase in Neurofibromatosis 1 mutant mice.
Krenik D; Weiss JB; Raber J
Brain Res; 2021 Oct; 1769():147594. PubMed ID: 34339711
[TBL] [Abstract][Full Text] [Related]
5. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
7. Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin.
Ruiz-DeDiego I; Fasano S; Solís O; Garcia-Montes JR; Brea J; Loza MI; Brambilla R; Moratalla R
Sci Rep; 2018 Oct; 8(1):15381. PubMed ID: 30337665
[TBL] [Abstract][Full Text] [Related]
8. Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.
Diggs-Andrews KA; Brown JA; Gianino SM; Rubin JB; Wozniak DF; Gutmann DH
Ann Neurol; 2014 Feb; 75(2):309-16. PubMed ID: 24375753
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of Anaplastic Lymphoma Kinase rescues spatial memory impairments in Neurofibromatosis 1 mutant mice.
Weiss JB; Weber S; Marzulla T; Raber J
Behav Brain Res; 2017 Aug; 332():337-342. PubMed ID: 28629962
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.
Anastasaki C; Woo AS; Messiaen LM; Gutmann DH
Hum Mol Genet; 2015 Jun; 24(12):3518-28. PubMed ID: 25788518
[TBL] [Abstract][Full Text] [Related]
11. A mouse model for the learning and memory deficits associated with neurofibromatosis type I.
Silva AJ; Frankland PW; Marowitz Z; Friedman E; Laszlo GS; Cioffi D; Jacks T; Bourtchuladze R
Nat Genet; 1997 Mar; 15(3):281-4. PubMed ID: 9054942
[TBL] [Abstract][Full Text] [Related]
12. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
13. Early postnatal l-Dopa treatment causes behavioral alterations in female vs. male young adult Swiss mice.
de Matos LO; de Araujo Lima Reis AL; Lopes Guerra LT; de Oliveira Guarnieri L; Moraes MA; Arabe LB; de Souza RP; Pereira GS; Souza BR
Neuropharmacology; 2020 Jun; 170():108047. PubMed ID: 32325324
[TBL] [Abstract][Full Text] [Related]
14. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK
BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690
[TBL] [Abstract][Full Text] [Related]
15. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
[TBL] [Abstract][Full Text] [Related]
16. HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.
Omrani A; van der Vaart T; Mientjes E; van Woerden GM; Hojjati MR; Li KW; Gutmann DH; Levelt CN; Smit AB; Silva AJ; Kushner SA; Elgersma Y
Mol Psychiatry; 2015 Nov; 20(11):1311-21. PubMed ID: 25917366
[TBL] [Abstract][Full Text] [Related]
17. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease.
Ambrée O; Richter H; Sachser N; Lewejohann L; Dere E; de Souza Silva MA; Herring A; Keyvani K; Paulus W; Schäbitz WR
Neurobiol Aging; 2009 Aug; 30(8):1192-204. PubMed ID: 18079024
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner.
Brown JA; Diggs-Andrews KA; Gianino SM; Gutmann DH
Mol Cell Neurosci; 2012 Jan; 49(1):13-22. PubMed ID: 21903164
[TBL] [Abstract][Full Text] [Related]
19. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.
Costa RM; Federov NB; Kogan JH; Murphy GG; Stern J; Ohno M; Kucherlapati R; Jacks T; Silva AJ
Nature; 2002 Jan; 415(6871):526-30. PubMed ID: 11793011
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
